Join to View Full Profile
1600 Divisadero StSan Francisco, CA 94143
Phone+1 415-353-9888
Fax+1 415-353-7150
Are you Dr. Tempero?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Margaret Tempero, MD is an oncologist in San Francisco, California. She is currently licensed to practice medicine in California and Iowa. She is a Professor of Medicine at UCSF.
Education & Training
University of Nebraska Medical Center College of MedicineFellowship, Hematology and Medical Oncology, 1982 - 1982- University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 1977 - 1980
University of Nebraska College of MedicineClass of 1977
Certifications & Licensure
CA State Medical License 2000 - 2025
IA State Medical License 1985 - 1999
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.Phoebe N Miller, Fernanda Romero-Hernandez, Lucia Calthorpe, Jaeyun Jane Wang, Sunhee S Kim
Annals of Surgical Oncology. 2024-09-01 - ASO Visual Abstract: Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic Cancer.Phoebe N Miller, Fernanda Romero-Hernandez, Lucia Calthorpe, Jaeyun Jane Wang, Sunhee S Kim
Annals of Surgical Oncology. 2024-07-27 - 23 citationsAmpullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology.E Gabriela Chiorean, Marco Del Chiaro, Margaret A Tempero, Mokenge P Malafa, Al B Benson
Journal of the National Comprehensive Cancer Network. 2023-07-01
Press Mentions
JCO Article Insights: Use of Independently-Assessed vs Investigator-Assessed DFS in the APACT TrialMay 15th, 2023- New Advisory Board Chair Has Been Part of PanCAN Since the BeginningJuly 7th, 2021
- The Pancreatic Cancer Action Network (PanCAN) Welcomes Two New Board Members and Scientific and Medical Advisory Board ChairJuly 6th, 2021
- Join now to see all
